Clinical trials: Diabetes, Type 1
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with type 1 diabetes.
- Trial name
- NCT02033239
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Hypoglycemia, Diabetes Mellitus, Type 1
A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare a needle-free treatment of hypoglycemia with nasal glucagon (study drug) to a marketed glucagon administered by the intramuscular (IM) route, in participants with type 1 diabetes mellitus…
- Trial name
- NCT03339453
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 2 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles
Anxiety about needles is a commonly expressed concern by diabetics about beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of currently marketed pen needles may…
- Trial name
- NCT00928057
- Testing
- 4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle
- Where
- 4 sites in United States
- Volunteers
- 173 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
The purpose of this study is to investigate the safety and tolerability of repeated doses of HM11260C when given different regimens in subjects with type 2 diabetes mellitus (T2DM) on stable metformin monotherapy.
- Trial name
- NCT01452451
- Testing
- HM11260C
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body)properties of FIAsp…
- Trial name
- NCT02003677
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 67 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the single dose and steady state pharmacodynamics of biphasic insulin aspart 30 and biphasic insulin aspart 70 in subjects with type 1 diabetes.
- Trial name
- NCT01526941
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 70
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Novo Nordisk A/S
Insulin Resistance, Lipohypertrophy
De-tensioning Patch, in Subjects With Type 1 Diabetes and Lipohypertrophy
This is a single-center, single-cohort, open, repeated-application study. Baseline assessments will include a Hyperinsulinemic clamp after injection of 0.15 U/kg body weight of insulin lispro in the target LH lesion, as well as a…
- Trial name
- NCT06025513
- Testing
- Embrace Patch
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Neodyne Biosciences, Inc.
Diabetes Mellitus
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus
The purpose of this study is to evaluate the safety and effectiveness of the G4 System when worn for up to 7-days by children and adolescent subjects (6 to <18 years-old) with type 1 diabetes mellitus.
- Trial name
- NCT01185496
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- DexCom, Inc.
Type 1 Diabetes Mellitus
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
This is a randomized, parallel group, double-blind Phase 2 study with a blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on…
- Trial name
- FABULINUS (NCT06111586)
- Testing
- Frexalimab, Insulin
- Where
- 79 sites in United States, Austria and 14 more
- Volunteers
- 197 people
- Sponsor
- Sanofi
Type 1 Diabetes
Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®
This is an extension study to evaluate the safety and tolerability of long-term treatment with DiaPep277® and to determine the long-term treatment effect of DiaPep277® on parameters of metabolic control and on preservation of…
- Trial name
- DIA-AID 2 (NCT01898286)
- Testing
- DiaPep277®
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Andromeda Biotech Ltd.
Diabetes, Diabetes Mellitus, Type 1
NovoLet® Acceptance Study Within the Hospital Practise in Indonesia
This study is conducted in Asia. The aim of this study is to evaluate the overall acceptance of healthcare professionals (nurses and doctors) to the NovoLet® system used in a hospital environment.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492205
- Testing
- insulin human
- Where
- Indonesia
- Volunteers
- 203 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks..
- Trial name
- PROTECT (NCT03875729)
- Testing
- teplizumab
- Where
- 62 sites in United States, Belgium and 7 more
- Volunteers
- 328 people
- Sponsor
- Provention Bio, Inc.
Type 2 Diabetes, Obesity
Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687
This is a study in Japanese healthy volunteers to determine the safety and tolerability of the compound AZD7687. It will also assess how the body handles the drug and how it responds to the drug following single dose followed by…
- Trial name
- JSMAD (NCT01217905)
- Testing
- AZD7687
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabete Type 2, Hypertension
A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian Participants
The goal of this Phase 1 clinical trial is to compare the pharmacokinetics and safety of a fixed-dose combination tablet (ATB-U101) versus co-administration of its individual components in healthy Caucasian adult volunteers.
- Trial name
- NCT07590466
- Testing
- ATB-U101, ATB-1011, ATB-U1011
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Autotelicbio
Diabetes Mellitus, Type 1
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.
- Trial name
- NCT04598893
- Testing
- Teplizumab
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 188 people
- Sponsor
- Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 2
A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics
The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
- Trial name
- NCT00886821
- Testing
- CVX-096
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Pfizer
Type 1 Diabetes
The Effect of Pramlintide on Meal Time Insulin Bolus
The primary objective is to establish the mean percentage of change in the insulin-to-carbohydrate ratio due to pramlintide treatment once a maximum tolerated dose or 6 mcg before each meal is reached.
- Trial name
- NCT00460304
- Testing
- pramlintide, continuous glucose monitoring
- Volunteers
- 12 people
- Sponsor
- Diabetes Care Center
Diabetes Mellitus, Type 1
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.
- Trial name
- NCT02038764
- Testing
- PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Advanced Clear Cell Renal Cell Carcinoma
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell…
- Trial name
- eVOLVE-RCC02 (NCT07000149)
- Testing
- Volrustomig, Casdatifan
- Where
- 3 sites in Australia, South Korea
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics.
- Trial name
- MIP310 (NCT00211536)
- Testing
- Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Medtronic MiniMed, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.